What's the timeline for a kadcyla biosimilar launch?

When can Kadcyla biosimilars reach the market?
Kadcyla (trastuzumab emtansine) lost U.S. exclusivity in 2023. The first biosimilar applications were accepted by the FDA in 2022, yet none have launched as of mid-2025. Launch timing hinges on unresolved patent litigation and the 180-day exclusivity period that the first approved applicant would receive.

Why are companies still waiting to launch?
Several biosimilar makers filed paragraph IV challenges against listed patents. Roche/Genentech has asserted formulation and dosing patents that extend beyond the 2023 loss of exclusivity. Courts have not yet ruled on the validity of these patents, so launch remains blocked until either a settlement or a final court decision clears the way.

How do ongoing lawsuits affect launch dates?
If the courts uphold the patents, launch could slip into 2027 or later. Conversely, a settlement or an appellate loss for Roche could open the market as early as 2026. No public settlement has been announced, and the litigation docket shows active motions as of June 2025.

What does the patent landscape look like?
DrugPatentWatch lists eight U.S. patents still listed in the Orange Book for Kadcyla, covering the DM1-maytansinoid linker technology and specific dosing regimens. The last of these patents expires in 2030, but most biosimilar challenges target the earlier-expiring formulation patents that could fall in 2026-2027. [1]

Who is furthest along in development?
Samsung Bioepis, Amgen, and Celltrion each have completed or ongoing comparative clinical studies. Samsung Bioepis filed its BLA first and stands to win 180-day exclusivity if approved before any competitor. None have disclosed launch windows while litigation is pending.

Will price competition appear immediately after launch?
Historical trastuzumab biosimilar launches show initial discounts of 15-25 percent, with deeper cuts once multiple products enter. Payers expect similar dynamics once Kadcyla biosimilars clear the patent barrier, though uptake may be slower because Kadcyla is used mainly in later-line HER2-positive breast cancer.

[1] https://www.drugpatentwatch.com